Cancer-related biological materials in microvesicles
Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.
1. A method for identifying the presence of a retrotransposon element in a microvesicle from a subject comprising the steps of:
a. isolating microvesicles derived from a tumor cell from the subject;
b. treating the isolated microvesicles with a combination of DNAse and Exonuclease III;
c. extracting at least one nucleic acid from the treated microvesicles; and
d. detecting the presence of the retrotransposon element in the extracted nucleic acid.
2. The method of claim 1 , wherein the retrotransposon element is LINE, SINE or HERV, or a fragment thereof.
3. The method of claim 2 , wherein the retrotransposon element is Line1 (L1), ALU, HERV-H, HERV-K, HERV-K6, HERV-W or HERV-C, or a fragment thereof.
4. A method for determining the expression level of a retrotransposon element in a microvesicle from a subject comprising the steps of:
a. isolating microvesicles derived from a tumor cell from the subject;
b. treating the isolated microvesicles with a combination of DNAse and Exonuclease III;
c. extracting at least one nucleic acid from the treated microvesicles; and
d. determining the expression level of the retrotransposon element biomarker in the extracted nucleic acid.
5. The method of claim 4 , wherein the retrotransposon element is LINE, SINE or HERV, or a fragment thereof.
6. The method of claim 5 , wherein the retrotransposon element is Line1 (L1), ALU, HERV-H, HERV-K, HERV-K6, HERV-W or HERV-C, or a fragment thereof.